Beschreibung:
<jats:title>Abstract</jats:title><jats:p>Dabigatran (Pradaxa) is a new oral anticoagulant licensed for the prevention of stroke in patients with atrial fibrillation and a risk factor for stroke. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse events compared with warfarin, and Professor Gregory Lip considers its potential role in therapy.</jats:p>